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Abstract 
Adriamycin (ADR) was formulated in albumin-heparin conjugate microspheres (AHCMS) to improve site-specific 
delivery and to reduce the toxicity of the drug. The effect of formulating ADR in AHCMS was investigated upon 
intrahepatic administration to male Wag/Rij rats. After intraveno-portal (i.v.p.) administration of ADR-AHCMS, 
ADR peak plasma concentrations were reduced 10-fold and ADR tissue levels of non-target issues were 
significantly reduced, as compared to i.v.p, administration of the free drug. At an i.v.p, administered drug dose of 7.5 
mg/kg, free ADR showed distinct signs of acute toxicity. At the same dose of ADR-AHCMS, signs of toxicity were 
absent. Cardiac function parameters which were determined using an isolated working heart model did not change 
as a result of i.v.p, administration of free ADR or ADR-AHCMS at a dose of 7.5 mg/kg. Heart weights of animals 
in the ADR-AHCMS or the free ADR groups, however, were significantly lower than controls. Dose tolerance 
studies after intrahepatic-arterial ( .h.a.) administration of free ADR, empty AHCMS and ADR-AHCMS in rats 
demonstrated that empty AHCMS are tolerated at a dose of 45 mg/kg. Free ADR was tolerated at a dose of 4 
mg/kg, whereas ADR-AHCMS were tolerated up to a dose of 10 mg ADR/kg, as indicated by the survival. 
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1. Introduction 
Adriamycin (ADR) is considered to be one of 
the most effective antineoplastic agents currently 
* Corresponding author. Tel. + 31-53-892976; Fax + 31-53- 
317202. 
used in cancer chemotherapy. The major draw- 
back in ADR chemotherapy is the toxicity of the 
drug. Anthracyclines like ADR carry the risk of 
potentially lethal cardiomyopathy, characterized 
clinically by biventricular, progressive congestive 
heart failure. The amount of myocardial damage 
is related to the cumulative dose, and at a stan- 
dard treatment of three weekly intravenous bolus 
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injections, the cumulative dose should not exceed 
450-550 mg/m 2 (Bielack et al., 1989). This maxi- 
mum allowable dose, however, is related to the 
dose schedule. Storm et al. (1989) found that 
reduction of cardiotoxicity induced by either con- 
tinuous infusion or liposomal encapsulation of 
ADR is most likely related to the reduction of 
peak plasma levels. Moreover, it has been re- 
ported that damage to heart muscle cells is mainly 
related to peak ADR concentrations and that at 
lower concentrations higher cumulative doses are 
tolerated (Bielack et al., 1989). In order to in- 
crease ADR dosages while minimising undesir- 
able side effects albumin-heparin conjugate mi- 
crospheres (AHCMS) were developed as 
biodegradable ion-exchange ADR carriers 
(Cremers et al., 1994a,b,c). Site-specific adminis- 
tration of ADR should decrease peak plasma 
concentrations and thus decrease the exposure of 
healthy tissues to ADR. In this paper toxicity and 
pharmacokinetic studies are described which were 
performed using intraveno-portal (i.v.p.) adminis- 
tration of ADR to male Wag/Rij rats, either as a 
free drug or formulated in AHCMS. In addition, 
cardiotoxicity of free ADR and ADR-AHCMS 
after i.v.p, administration to rats was studied us- 
ing an isolated working-heart model (Wondergem 
et al., 1991). Finally, dose tolerance of free ADR 
and ADR-AHCMS upon intrahepatic administra- 
tion via the hepatic artery (i.h.a.) was studied in 
healthy Wag/Rij rats. 
2.2. Animals 
Male Wag/Rij rats, 8-12 weeks old and 
weighing 260 + 40 g at the time of the experi- 
ments, were bred at the animal department of 
The Netherlands Cancer Institute (Amsterdam, 
The Netherlands) under specific pathogen-free 
(SPF) conditions or obtained from the Centraal 
Proefdieren Bedrijf (T.N.O., Rijswijk, The 
Netherlands). The animals were kept on a 12 h 
light-12 h dark cycle and fed standard rat chow 
and plain tap water ad libitum. 
2.3. Microsphere suspensions 
ADR-AHCMS were resuspended (using a 
minimal amount of ethanol for wetting of the 
microspheres) in 5% w/v glucose solution. After 
2 h of rotation at 4°C in the dark, the micro- 
spheres were centrifuged and the supernatant 
was decanted. The ADR release in this washing 
solution was measured by UV/Vis spectroscopy 
at A494 using a Uvikon 930 spectrophotometer 
(Kontron Instruments, Rotkreuz, Switzerland). 
Fresh glucose solution was added to the micro- 
spheres to give the final concentration needed in 
the experiments. 
2.4. ADR-plasma levels and tissue distributions af- 
ter i.v.p, administration of free ADR and ADR- 
AHCMS in rats 
2. Materials and methods 
2.1. Materials 
Albumin-heparin conjugate microspheres 
(AHCMS) with a diameter of 10-25 /zm (dried) 
were prepared by crosslinking with 0.5% glu- 
taraldehyde as described previously (Cremers et 
al., 1994a). Adriamycin • HC1 was a kind gift from 
Pharmachemie, Haarlem, The Netherlands. Adri- 
amycin-loaded microspheres (ADR-AHCMS) 
were obtained by loading AHCMS with ADR up 
to a payload of 25.4% w/w as described previ- 
ously (Cremers et al., 1994c). 
2.4.1. Surgical procedure of i.v.p, administration 
Under ether anaesthesia, a midline laparotomy 
was performed and a loop of the small intestine 
was exposed. Free ADR or ADR-AHCMS (both 
corresponding to 5 mg ADR/kg), dissolved or 
resuspended in 0.5 ml 5% w/v glucose solution, 
was slowly injected into a mesenteric vein under 
microscopic observation using a 30 gauge needle. 
Afterwards, the vein was ligated. To increase the 
efficiency of the injection in the case of ADR- 
AHCMS, the syringe used was refilled with 0.5 ml 
of 5% w/v glucose solution and this was injected 
into another mesenteric vein. The amount of 
ADR injected was determined from the remain- 
der of ADR-AHCMS in the syringe using HPLC 
analysis, carried out as described below. 
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2. 4. 2. Plasma pharmacokinetics and tissue distribu- 
tion 
Rats were anaesthetized using ether and a 
catheter was introduced into the ascending aorta 
via carotid artery cannulation. Blood samples 
were drawn at t = 0, 5, 15, 30, 60, 120 and 240 
min after administration of free ADR or ADR- 
AHCMS. Blood samples were stored at -20°C 
until determination of the ADR content, which 
was performed as described below. To determine 
the ADR tissue distributions, rats were killed at 
15, 60 and 240 min after administration of the 
drug. Blood samples were taken and lung, heart, 
intestine, spleen, kidney and liver were removed 
and stored at -20°C until ADR extraction and 
determination of the ADR content, which were 
performed as described below. 
2.4.3. Adriamycin tissue extraction 
Approx. 1 g of tissue was weighed into a 50 ml 
Falcon®tube. After addition of 1 ml of distilled 
water and 10 /.~1 internal standard (IS; 4-de- 
oxydoxorubicinol) solution, the tissue was homog- 
enized. Then, 2 ml of borate buffer (2.5 M, pH 
9.2) was added. Organic phase (7 ml of 
CHC13/CH3OH, 4:1), was added and the mix- 
ture was vortexed for 1 min. After centrifugation 
(10 rain, 4000 rpm) the aqueous phase was re- 
moved. The remaining organic phase which con- 
tained IS, ADR and ADR metabolites was trans- 
ferred to silanized glass vials. The solvent was 
evaporated at 50°C under nitrogen flow and the 
remainder was redissolved in 200/~1 of the HPLC 
mobile phase. Before injection in the HPLC sys- 
tem the solution was centrifuged for 20 min at 
13 000 rpm. A calibration curve was determined 
from known amounts of ADR and IS that had 
been added to tissue samples from untreated 
rats, prior to homogenization. Calibration sam- 
ples were further handled in the same way as the 
other samples. 
2.4.4. HPLC analysis of ADR samples 
ADR concentrations of the blood samples and 
the tissue extracts were determined using HPLC 
according to a standard procedure that was de- 
scribed previously (Cremers et al., 1994c). ADR 
tissue levels were calculated from the calibration 
curve using the log ratio of the peak heights of 
ADR and IS. Various metabolites were detected, 
but they did not interfere with ADR or IS. 
2.5. ADR and ADR-AHCMS cardiotoxicity in iso- 
&ted working rat heart model 
Animals were given ADR or ADR-AHCMS 
i.v.p, as described above in three groups of 15 
rats each. Rats of the first group were treated 
i.v.p, with 7.5 mg/kg of free ADR. Animals in 
the second group were administered i.v.p. ADR- 
AHCMS, corresponding to a dose of 7.5 mg of 
ADR/kg.  The third group received no treatment 
and served as a control. After administration of 
ADR or ADR-AHCMS, rats were weighed weekly 
and blood samples were drawn from the tail vein 
every week. Haematocrit, haemoglobin content, 
leucocyte count, and urea and creatinine levels 
were determined as parameters for systemic toxi- 
city. After 8 weeks, the animals were killed as 
described below. Heart, kidneys and liver were 
removed and after the perfusion experiment, his- 
tological slides were made. For light microscopic 
evaluation, tissues of heart and kidney were fixed 
in 4% formaldehyde and embedded in paraffin 
Paraclean ®and sections of 5-6 /zm were made 
and stained with hematoxylin and eosin (H/E) .  
The heart was isolated as described by Won- 
dergem et al. (1991). When the heart had been 
cooled for 30-60 s and dissected, it was lifted 
from the cold buffer with a blunt forceps and the 
aortic stump was fixed to the aortic cannula of 
the perfusion apparatus and after allowing the 
heart to recover, cardiac function was tested as 
described by Wondergem et al. (1991). 
2.6. Dose tolerance of ADR-AHCMS after i.h.a. 
admin&tration in rats 
At day 0, male Wag/Ri j  rats were adminis- 
tered increasing doses of free ADR (5, 7.5, 10 
mg/kg, n = 3 per group) or ADR-AHCMS (5, 
7.5, 10, 15 mg ADR/kg,  n = 3 per group) via the 
hepatic artery as described below. 12 rats (four 
groups, six rats each) were administered a dose of 
empty AHCMS, comparable with the ADR- 
AHCMS doses, to determine the influence of the 
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embolization effect. Furthermore, two rats served 
as a control and received a sham operation and 
were administered 5% w/v glucose solution. Sur- 
vival of the animals was followed up to 28 days 
and the body weights were monitored at day 0, 4, 
7, 11, 14, 17, 22 and 25. Nephrotoxicity and 
hepatic toxicity were determined at day 14 by 
measurement of creatinine and urea levels, and 
y-glutamyl transferase (y-GT), serum glutamate 
oxaloacetate ransaminase (SGOT), serum gluta- 
mate pyruvate transaminase (SGPT) and alkaline 
phosphatase (AF) levels, respectively. 
2. 6.1. Surgical procedure of i.h.a, administration 
Animals were anaesthetized using 1/~l/g body 
weight of a mixture of 0.2 ml 2% w/v thiazine 
solution (Rompun ®, Bayer, Germany) and 0.8 ml 
10% w/v ketamine solution (Aescoket ®, Aescu- 
laap BV, The Netherlands), and an upper middle 
laparotomy was performed. Under microscopic 
observation, the common bile duct was dissected 
and a vessel oop was placed around it to be used 
as a tractor. Subsequently, the hepatic artery was 
dissected from the celiac trunk up to the conflu- 
ence with the gastroduodenal rtery. Then the 
gastroduodenal rtery was isolated over 0.5 cm 
and a proximal and a distal 4/0 silk loop was 
placed. The distal one was tightened and the 
proximal one was pulled up in order to stretch 
the artery and to avoid bleeding when the artery 
was opened. A partial cut of the lumen of the 
artery was performed using microscissors and a 
small catheter (2 French gauge) was inserted into 
the gastroduodenal artery and pushed up to the 
hepatic artery. The catheter was maintained in its 
place by soft pressure with dissection forceps, 
meanwhile the infusion of ADR solution or empty 
or ADR loaded AHCMS suspension in 5% w/v 
glucose solution was carried out. After the infu- 
sion, the catheter was removed, the proximal 
ligature was tightened and the abdominal wound 
was closed. 
3. Results and discussion 
AHCMS and ADR-AHCMS were prepared 
according to standard procedures previously de- 
scribed by Cremers et al. (1994a,c). ADR release 
from ADR-AHCMS during the washing step in 
the suspension procedure of the microspheres in
aqueous medium was as described previously 
(Cremers et al., 1994c). The amount of drug 
released in this washing step varied between 2 
and 30% w/w of the incorporated drug depend- 
ing on the batch of ADR-AHCMS used. This was 
taken into account in the preparation of the 
injections. 
3.1. ADR plasma levels and tissue distributions 
after Lu.p. administration of free ADR and ADR- 
AHCMS in rats 
To determine the drug targeting and con- 
trolled release fficiency of ADR-AHCMS, ADR 
plasma levels and tissue distributions were mea- 
sured after i.v.p, injection of free drug and micro- 
sphere-formulated drug. ADR clearance from 
blood after administration of 5 mg ADR/kg, 
either as free drug or as ADR-AHCMS, is shown 
in Fig. 1. 
In the free ADR group the concentration of
ADR in blood decreased rapidly and remained 
nearly constant at a low level. The initial rapid 
decrease in ADR concentration results from the 
distribution of ADR over tissues. This phase is 
followed by a slower elimination phase as a con- 
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Fig. 1. Mean ADR concentrations in blood of Wag/Rij  rats 
after i.v.p, administration of 5 mg ADR/kg.  (e) Free ADR 
(n = 6); (o)  ADR-AHCMS (n = 4). Error bars indicate SD. 
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sequence of renal clearance and metabolism. This 
was also found by Camaggi et al. (1988). If the 
drug was administered as ADR-AHCMS, a com- 
parable profile was observed, although the drug 
peak levels at t = 5 min were about one-tenth of 
that after administration of free ADR. Overall, 
the blood ADR concentration of free ADR was 
higher than that of ADR-AHCMS, and although 
the same dose was given, the area under the 
curve (AUC) of ADR-blood is smaller in the case 
of ADR-AHCMS as compared with free ADR 
(AUCf ree  ADR > AUCADR-AHCMS)" This may be 
due to more extensive metabolism of ADR in the 
liver when administered as ADR-AHCMS. Intra- 
veno-portal (i.v.p.) administration of ADR- 
AHCMS causes vascular occlusion whereupon 
ADR can be released locally (Cremers et al., 
1994b). Therefore, more ADR is present in the 
liver and may be metabolized more extensively. 
Indications for this were observed in HPLC chro- 
matograms of liver tissue extracts (data not 
shown). The formation of metabolites by biore- 
duction of ADR was previously reported by Will- 
mott et al. (1990). These metabolites, however, 
were not analysed in this study. As already men- 
tioned above, peak plasma levels were 10-times 
lower if ADR was given i.v.p, as ADR-AHCMS 
instead of free drug. It is therefore concluded 
that the use of ADR-AHCMS could prevent ad- 
verse effects related to high peak plasma levels of 
the drug. 
The ADR tissue distributions after i.v.p, ad- 
ministration of ADR and ADR-AHCMS at a 
dose of 5 mg ADR/kg are shown in Fig. 2. The 
tissue levels were corrected for the amount of 
administered drug and differences in the extrac- 
tion efficiency of IS and ADR in the various 
tissues. Tissue levels were also corrected for ADR 
present in the blood in the tissue. Fig. 2a and b 
shows that the ADR levels in non-target tissues 
upon administration fADR-AHCMS were lower 
than those after injection of free ADR. The ADR 
levels in the liver in the free drug group remained 
constant at approx. 15-20/zg/g for 240 min. In 
the ADR-AHCMS group, however, the initial 
ADR level was much higher (37/zg/g), and de- 
creased to a level 4-times lower (4.5/zg/g) than 
that of the free drug group at t = 240 rain. The 
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Fig. 2. ADR tissue levels at 15, 60 and 240 min after i.v.p. 
administration of 5 mg/kg ADR in male Wag/Ri j  rats. (a) 
Free ADR (nt5 = 3, n60 = 3, n240 = 4); (b) ADR-AHCMS 
(n=2) .  (11) Lung; (B )  liver; ([])  spleen; ([])  kidney; ([3) 
heart; ( [ ] )  intestine. Error bars in (a) indicate SD; error bars 
in (b) denote range of observations. 
larger decline of the ADR content in the liver 
may also be explained by the enhanced 
metabolism, due to increased bioreduction. It 
should be taken into account, however, that the 
initially higher drug content, measured in liver 
tissue after ADR-AHCMS administration, may 
be a consequence of ADR present in AHCMS 
lodged in the liver, which had not been released 
at that time. Nevertheless, whether the drug is 
present in the tissue itself or is still entrapped in 
microspheres in the tissue, it may be concluded 
that targeting of the drug to the liver using 
AHCMS is effective, since initially higher drug 
levels are achieved while minimising non-target 
56 H.F.M. Cremers et aL / International Journal of Pharmaceutics 120 (1995) 51-61 
20 
15 e., 
"6 
0 
@ 
{ s 
i 
0 60 
! 
120 
time [min] 
i i 
180 240 
Fig. 3. Liver to heart ratio of ADR tissue levels after i.v.p. 
administration of 5 mg ADR/kg to male Wag/Rij rats. (e) 
Free ADR; o: ADR-AHCMS. 
tissue levels. Moreover, the reduction of ADR 
heart levels which are approx. 5-times lower if the 
drug is administered in microspheres, is most 
important considering the cardiotoxicity of the 
drug. The increased targeting efficiency by formu- 
lation of the drug in AHCMS is thus demon- 
strated by the ratios of ADR in liver and heart 
tissue, shown in Fig. 3. The increased liver to 
heart ratios, after administration of ADR- 
AHCMS, indicate improved site-specific drug de- 
livery. 
3.2. ADR and ADR-AHCMS cardiotoxicity in iso- 
lated working rat heart model 
General toxicity of ADR after i.v.p, adminis- 
tration as free drug or as microsphere-formulated 
drug was studied in Wag/Rij rats. In the first 
group (n -- 15), the rats were administered a dose 
of 7.5 mg ADR/kg, as a free drug. Due to high 
injection efficiency in the case of ADR-AHCMS, 
rats of the second group (n = 15) were adminis- 
tered 8.0 mg ADR/kg as a microsphere formula- 
tion. The third group (n = 15) served as a control 
group and was not treated. Two animals, one in 
each treatment group, died within 24 h after 
injection. During the experiment, six more ani- 
mals in the free drug treated group died. In both 
treatment groups the body weight of the animals 
decreased as compared to the control animals. In 
the case of the ADR-AHCMS treated animals 
there seemed to be some recovery from the initial 
toxicity, since these animals tarted to gain weight 
again from 2 weeks on, whereas the free drug 
treated group continued losing weight during the 
experiment. Differences between the three groups 
were significant (p < 0.05). 
In the free drug treated group, the haemat- 
ocrit and the haemoglobin content decreased im- 
mediately compared with the controls, whereas 
no differences were observed between the con- 
trois and the ADR-AHCMS treated group. The 
leucocyte count in the free ADR group at 1 week 
post-administration was only 30% of that of the 
controls. In the ADR-AHCMS treated group the 
leucocyte count was initially 70% of that of the 
controls, but was restored after approx. 4 weeks. 
This is in agreement with the results of Codde et 
al. (1990) which reported leucopenia following 
intra-arterial and intravenous administration of 
free ADR, whereas administration f ADR bound 
to sulphonated polystyrene microspheres did not 
significantly reduce the white blood cell count. 
Already 1 week post treatment, measurements 
of haematological parameters (leucocyte count, 
haematocrit, haemoglobin, urea and creatinine 
content) became impossible in the free ADR 
treated group. Blood coagulated espite the hep- 
arin. The serum was also turbid, which was as- 
cribed to hyperlipidaemia as could be shown by 
centrifugation of the serum. Bizzi et al. (1983) 
reported hyperlipidaemia in male CD-COBS rats 
14-21 days after administration of a single dose 
of ADR (7.5 mg/kg), resulting from a developing 
nephrotic syndrome. The rats in the free ADR 
treated group also had diarrhoea and ascites. 
Renal damage in this group was indicated by urea 
and creatinine levels which increased within 1 
week, whereas the urea and creatinine levels in 
the control group and the ADR-AHCMS treated 
group remained at a constant level. 8 weeks after 
treatment, kidneys were removed and histological 
examination showed severe damage of the kid- 
neys in the free ADR treated groups. In the 
kidneys of this group, vacuoles in the glomeruli, 
glomerular sclerosis, tubular dilatation, dense 
protein casts and interstitial fibrosis with cell 
infiltration were observed. No differences were 
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observed between kidneys of the ADR-AHCMS 
treated group and the controls (data not shown). 
Nephrotic syndrome was probably the main cause 
of death in the animals in the free ADR treated 
group. This agrees with reports of Storm et al. 
(1989) who concluded that ADR-induced 
nephropathy represents an important cause of 
death in experimental nimals. 
The cardiotoxicity ofADR and ADR-AHCMS 
was evaluated using an isolated working heart 
model. In Table 1 several cardiac performance 
parameters, together with the body and heart 
weight of the animals in the different reatment 
groups are presented. Table 1 shows that no 
significant differences in the cardiac performance 
parameters were found. At histological examina- 
tion, prominent histopathological differences be- 
tween the three groups were absent. In both drug 
treated groups, however, some fibrillar loss was 
observed. Macroscopically, the hearts from the 
free drug treated group seemed somewhat flabby 
in comparison with hearts in the other groups 
and the left ventricular wall of these hearts was 
thinner than that of the two other groups. 
Although heart weights were significantly de- 
creased in ADR treated animals in both treat- 
ment groups and some heart damage was ob- 
served on a microscopic level in the free drug 
treated group, no significant changes in cardiac 
function were measured. It has been reported 
that morphological nd histological changes do 
not always correlate with loss of cardiac function. 
lsner et al. (1983) found that 35% of patients 
with impaired left ventricular systolic perfor- 
mance had no light microscopic histological signs 
of toxicity, whereas in 52% of the patients with- 
out clinical toxicity, histological abnormalities 
were present. Reeves et al. (1990) suggested that 
the prediction and quantitation of ADR car- 
diotoxicity based on light microscopic hanges is 
uncertain. An explanation for lack of functional 
impairment may be that both peak plasma levels 
and cumulative doses are important factors in the 
development of cardiac disfunction. Iatropolous 
(1984) reported that the earliest evidence for 
ADR associated cardiomyopathy was morpholog- 
ical, followed by clinical signs after two to five 
additional doses. Cummings and Smyth (1988) 
reported that ADR-induced cardiotoxicity has 
been more closely linked with repeated drug 
treatment. Yeung et al. (1989), however, studied 
changes in cardiac function in Sprague Dawley 
rats after a single intravenous ADR injection of 
1-4 mg/kg. There was an initial phase of rapid 
decline in cardiac output in the first 12 weeks and 
a second phase of persistent depression in car- 
diac function. These data suggest that strain dif- 
ferences may play an important role in the devel- 
opment of cardiomyopathy. This was also re- 
ported by Jaenke and Fajardo (1977) who found 
species and strain related variations in toxicity of 
anthracyclines in kidney and heart. 
Since in rats the chronic toxicity of ADR not 
only includes cardiotoxicity but also nephrotoxic- 
ity, the question was raised whether nephrotoxic- 
ity adds to or even might be responsible for 
ADR-induced cardiotoxicity in rats, in fact it was 
suggested by Van der Vijgh et al. (1978) that 
Table 1 
Cardiac performance and body and heart weights a of ADR-treated animals measured in an isolated working heart model at a left 
atrial filling pressure of 15 cmH20 and at an aortic pressure of 90 cmH20 
Control (n = 12) Free ADR (n = 6) ADR-AHCMS (n = 12) 
Body weight (g) 302.0 + 5.5 197.9 _+ 6.3 b,c 261.9 + 8.6 b 
Heart weight (g) 1.2 _+ 0.0 0.9 + 0.0 b.c 1.1 _+ 0.1 b 
HW/BW 0.4 _+ 0.0 0.5 _+ 0.0 0.4 _+ 0.0 
Heart rate (beats/min) 175.8 _+ 13.0 148.7 _+ 11.2 170.3 _+ 12.0 
Coronary flow (ml/min) 11.4 ± 1.0 8.6 _+ 0.5 11.7 _+ 1.2 
Cardiac output (ml/min) 28.9 _+ 2.8 24.5 _+ 3.2 30.7 _+ 3.0 
a Parameters are expressed as mean + SE. 
b Significantly different from controls, p < 0.05. 
c Significantly different from ADR-AHCMS treated group, p < 0.05. 
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cardiotoxicity of ADR in rats is partly related to 
concomitant nephrotoxicity. In our study, how- 
ever, nephrotoxicity was evident without loss of 
cardiac function. In a study of Van Hoesel et al. 
(1986) it was concluded that cardiomyopathy ob- 
served in Lou /M rats is a simultaneous phe- 
nomenon independent of nephropathy. 
From the initial decrease in body weights of 
treated animals, it can be concluded that, at an 
ADR dose of 7.5 mg/kg, the drug is toxic to the 
animals. ADR-AHCMS treated animals started 
gaining weight again whereas free drug treated 
animals continued losing weight, demonstrating 
reduced toxicity of the microsphere formulated 
drug. The same trend was observed from the 
survival of the animals, seven animals in the free 
drug treated group died whereas in the ADR- 
AHCMS group only one animal died. From the 
evaluation of the haematological parameters it
was also concluded that the ADR-AHCMS was 
less toxic than free ADR. In the latter group 
leucocyte count, haemoglobin content and 
haematocrit was significantly decreased, whereas 
there was no difference between the ADR- 
AHCMS treated animals and the controls, except 
for a transient small decrease in the leucocyte 
count, as far as these parameters are concerned. 
Nephrotoxicity was manifest in the free ADR 
treated group, while there was no change in renal 
function and kidney histology in ADR-AHCMS 
treated animals and controls. Overall, these re- 
sults suggest hat the toxicity of the drug is re- 
duced when formulated in AHCMS. 
3.3. Dose tolerance of ADR-AHCMS after i.h.a. 
administration in rats 
Administration of ADR-AHCMS into the hep- 
atic artery (i.h.a.) of Wag/Ri j  rats was more 
difficult than i.v.p, administration. The i.h.a, ad- 
ministration was carried out by injection into a 
small-diameter catheter. Injecting ADR solutions 
was no problem. Injection of ADR-loaded or 
empty AHCMS was more difficult, because the 
catheter was sometimes occluded by the micro- 
spheres and it was laborious to empty the syringe 
completely. This is reflected in Table 2 by the 
differences between the planned dose and the 
administered dose. In the case of empty AHCMS, 
61-100% of the particles was injected, whereas in 
the case of ADR-AHCMS only 45-52% was in- 
jected. ADR-AHCMS tended to aggregate and to 
stick to the wall of the syringe, a problem which 
was not observed with empty AHCMS. Table 2 
also shows that the administration of micro- 
spheres was not very reproducible, which is indi- 
cated by the standard eviation (SD) of the means. 
Fig. 4 demonstrates the survival of individual 
animals as a function of the administered oses 
of ADR. Fig. 4 shows that administrations of 
Table 2 
Planned and injected doses of ADR, AHCMS and ADR-AHCMS administered i.h.a, to male Wag/R i j  rats in dose tolerance 
experiment 
Group Planned dose (mg/kg)  Administered ose (mg/kg)  a 
(ADR-)AHCMS ADR (ADR)-AHCMS ADR 
ADR-1 
ADR-2 
ADR-3 
AHCMS-1 15.00 
AHCMS-2 22.50 
AHCMS-3 30.00 
AHCMS-4 45.00 
ADR-AHCMS-1 20.00 
ADR-AHCMS-2 30.00 
ADR-AHCMS-3 40.00 
ADR-AHCMS-4 60.00 
5.00 
7.50 
10.00 
12.44 + 1.36 
13.85 + 4.65 
20.32 + 6.71 
45.90 ± 26.15 
5.00 10.26 ± 0.25 
7.50 13.72 ± 1.27 
10.00 21.10 ± 0.35 
15.00 30.43 + 14.02 
6.08 + 0.46 
9.93 + 0.33 
11.88 + 1.45 
2.68 + 0.07 
3.58 ± 0.33 
5.51 + 0.09 
7.94 ± 3.66 
a Mean ± SD. 
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Fig. 4. Survival of maleWag/Rij rats after i.h.a, administra- 
tion of ADR as a function of the drug dose. ([]) Free ADR; 
(z~) ADR-AHCMS; (o)  control. Each point represents one 
animal. 
ADR-AHCMS up to a level of 10 mg ADR/kg  
are tolerated, even though two rats died at lower 
doses (cause unknown). For free drug there is a 
distinct decrease in survival times with increasing 
drug dose, although individual differences are 
obvious. From Fig. 4 the maximum allowable 
dose of free ADR is estimated to be approx. 4 
mg/kg. 
The differences in the dose tolerance of the 
ADR-formulations was also indicated by the 
changes of the average body weights of the ani- 
mals in each group. The animals treated with the 
free drug lost weight, indicative of severe toxicity, 
with most animals dying within 20 days. One 
animal treated at the lowest dose of free ADR 
(ADR-1), survived and recovered, which was indi- 
cated by the weight gain of this animal. Animals 
treated with empty microspheres at any dose grew 
at the same rate as the control animals. The 
animals treated with the ADR-AHCMS initially 
lost weight, but after approx. 5 days the animals 
seemed to recover and gained weight again. 
From the biochemical determination listed in 
Table 3 it can be seen that in the lowest free 
ADR group (ADR-1), there is a very mild change 
of the renal function, indicated by a small in- 
crease in urea levels, while creatinine levels are 
maintained at a normal level. In the 7.5 mg/kg 
group (ADR-2), there was only one animal alive 
at the time of the biochemical determination, and 
its values showed a greater change in the renal 
function. In most of the animals in the free drug 
group, there was a decrease in the alkaline phos- 
phatase (AF) levels which is difficult to explain. 
The biochemical determinations of most ani- 
mals in the empty AHCMS groups, were normal 
at all doses, but sometimes a mild change of the 
renal function was detected, which could not be 
correlated with the dose. No changes in the hep- 
atic function were observed in any AHCMS group. 
In the ADR-AHCMS groups there is a progres- 
sive deterioration in renal function which was 
correlated with the increase in dosage of ADR- 
AHCMS. No alterations of the hepatic function 
were detected in this group, which is in agree- 
ment with the results previously reported by Cre- 
mers et al. (1994b). 
Overall, survival, body weights, and l~idney and 
liver parameters of Wag/Ri j  rats, after i.h.a, ad- 
Table 3 
Kidney and liver parameters of male Wag/Rij  rats, 14 days 
after i.h.a, administration of ADR, empty AHCMS or ADR- 
AHCMS 
Group a Creati- Urea g-GT SGOT SGPT AF 
nine 
Control 83 12.8 43 73 49 109 
85 10.6 43 66 39 121 
ADR-1 100 35 - - - 
49 9.3 1 64 36 48 
106 18.5 2 86 34 53 
ADR-2 125 75.9 43 158 48 35 
AHCMS-1 88 9 3 54 39 211 
AHCMS-2 138 16.4 43 54 46 150 
77 9.7 43 53 42 138 
214 33 43 72 47 47 
AHCMS-3 127 16.4 43 52 44 160 
109 14.1 43 52 44 139 
AHCMS-4 66 9.6 43 72 49 148 
116 14.7 3 52 40 154 
ADR-AHCMS-1 66 10.6 43 64 38 126 
138 21.2 43 55 41 63 
74 9.3 43 48 45 154 
ADR-AHCMS-2 83 11.8 43 52 42 139 
118 15.6 43 51 45 159 
ADR-AHCMS-3 153 19 3 51 49 148 
155 19.3 5 59 38 218 
ADR-AHCMS-4 144 14.8 3 47 41 140 
282 27.6 9 55 38 135 
a Codes are explained in Table 2. 
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ministration of free ADR,  AHCMS and ADR- 
AHCMS suggest that the adriamycin toxicity is 
reduced if the drug is formulated in AHCMS. At 
higher dosages, ADR-AHCMS are better toler- 
ated than free ADR. Intrahepato-arterial admin- 
istration of empty AHCMS was tolerated at any 
dose tested. From these results it is concluded 
that in the case of i.h.a, administration in 
Wag/R i j  rats, free ADR is tolerated at a dose of 
4 mg/kg,  whereas in the case of ADR-AHCMS, 
a dose of 10 mg ADR/kg  could be administered. 
4. Conclusions 
Albumin-hepar in  conjugate microspheres 
loaded with adriamycin can be used for site- 
specific delivery of the drug. After intrahepatic 
administration of the drug by i.v.p, injection, adri- 
amycin peak plasma concentrations and non- 
target tissue levels were significantly reduced, 
whereas drug levels in the target tissue were 
initially increased, if the drug was formulated in 
AHCMS (as compared with administration of free 
drug). Adriamycin cardiotoxicity could not be de- 
termined using cardiac performance parameters, 
since these parameters were influenced neither 
by free drug nor by ADR-AHCMS at the given 
dose and time scale. Acute toxicity after i.v.p. 
administration as determined by body weight, 
leucocyte count, haematocrit, and haemoglobin, 
urea and creatinine levels, however, demon- 
strated that at the same drug dose ADR-AHCMS 
is tolerated better than free ADR. 
Administration of ADR, AHCMS and ADR-  
AHCMS into the hepatic artery also demon- 
strated that the microsphere formulated drug is 
less toxic than free ADR. At the same drug dose, 
survival of animals is increased, and animals re- 
cover from initial weight loss due to acute toxicity 
if the drug is administered as ADR-AHCMS 
instead of free ADR. Nephrotoxicity increased 
with increasing drug dosages with higher doses 
being tolerated if the drug is formulated in 
AHCMS as compared to free ADR. Survival, 
changes in body weight and biochemical parame- 
ters of animals treated with empty AHCMS did 
not markedly differ from the controls, which only 
received a sham operation indicating that the 
empty microspheres are not toxic to the liver 
tissue. 
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